Cited 0 times in
Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고윤우 | - |
dc.contributor.author | 김다희 | - |
dc.contributor.author | 김세헌 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 박영민 | - |
dc.date.accessioned | 2023-04-07T01:18:05Z | - |
dc.date.available | 2023-04-07T01:18:05Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 2092-5859 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193873 | - |
dc.description.abstract | Background and Objectives We analyzed surgical outcomes, perioperative complications, and mortality in head and neck squamous cell carcinoma (HNSCC) in patients who underwent curative surgery following neoadjuvant immunotherapy. Subjects and Method The records of 36 HNSCC patients who underwent curative surgery with neoadjuvant immunotherapy and 69 HNSCC patients who received neoadjuvant chemotherapy were analyzed. Results The average operation time was 315 minutes, and the average bleeding volume was 167 cc. The average length of hospital stay was 21 days. When evaluating surgical margin status, we found 24 patients (66.6%) who exhibited a negative margin. We found no case where surgery was impossible due to progression of the lesion during neoadjuvant immunotherapy. Compared to the neoadjuvant chemotherapy group, neoadjuvant immunotherapy group showed acceptable perioperative safety and complication profile. The postoperative complication rate was 19.4% in the neoadjuvant immunotherapy group and 13.0% in the neoadjuvant chemotherapy group (p=0.386). There were no serious complications during the recovery period after surgery or instances of death due to complications. Conclusion In HNSCC patients, there was no increase in the incidence of complications or mortality related to curative surgery after neoadjuvant immunotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한이비인후과학회 | - |
dc.relation.isPartOf | Korean Journal of Otorhinolaryngology-Head and Neck Surgery | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes | - |
dc.title.alternative | 국소 진행성 두경부암 환자에서 선행면역치료 후 수술적 치료: 수술 전후 합병증 및 치료 결과 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Otorhinolaryngology (이비인후과학교실) | - |
dc.contributor.googleauthor | Ju Ha Park | - |
dc.contributor.googleauthor | Young Min Park | - |
dc.contributor.googleauthor | Da Hee Kim | - |
dc.contributor.googleauthor | Se-Heon Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Yoon Woo Koh | - |
dc.identifier.doi | 10.3342/kjorl-hns.2022.00283 | - |
dc.contributor.localId | A00133 | - |
dc.contributor.localId | A04831 | - |
dc.contributor.localId | A00605 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01566 | - |
dc.relation.journalcode | J02089 | - |
dc.identifier.eissn | 2092-6529 | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Neoadjuvant therapy | - |
dc.subject.keyword | Postoperative complications | - |
dc.contributor.alternativeName | Koh, Yoon Woo | - |
dc.contributor.affiliatedAuthor | 고윤우 | - |
dc.contributor.affiliatedAuthor | 김다희 | - |
dc.contributor.affiliatedAuthor | 김세헌 | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.contributor.affiliatedAuthor | 박영민 | - |
dc.citation.volume | 65 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 610 | - |
dc.citation.endPage | 616 | - |
dc.identifier.bibliographicCitation | Korean Journal of Otorhinolaryngology-Head and Neck Surgery, Vol.65(10) : 610-616, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.